Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

IMPORTANCE: Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Raut, Chandrajit P., Espat, N. Joseph, Maki, Robert G., Araujo, Dejka M., Trent, Jonathan, Williams, Toni Faith, Purkayastha, D. Das, DeMatteo, Ronald P.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2018
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440723/
https://ncbi.nlm.nih.gov/pubmed/30383140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4060
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky